Lenfomalar ve Paraneoplastik Sendromlar
Özet
Lenfomalar, immün sistemin temelini oluşturan lenfositlerden köken alan ve organizmada geniş klinik yansımalara yol açabilen malignitelerdir. Non-Hodgkin ve Hodgkin lenfoma olarak iki ana gruba ayrılan bu hastalıklar, direkt tümör etkisi veya metastazla ilişkili olmayan paraneoplastik sendromlara (PNS) sıklıkla zemin hazırlar. Lenfomalarda en sık görülen PNS belirtileri ateş, kilo kaybı ve gece terlemesidir; klinik uygulamalarda ise bu sendromlar hematolojik, nörolojik, dermatolojik ve renal bozukluklar olmak üzere dört ana başlıkta incelenir. Hematolojik olarak otoimmün hemolitik anemi ve immün trombositopeni öne çıkarken; nörolojik alanda paraneoplastik serebellar dejenerasyon, limbik ensefalopatiler ve periferik nöropatiler gözlenir. Dermatolojik olarak paraneoplastik pemfigus ve Sweet sendromu, renal alanda ise minimal değişiklik hastalığı gibi nefrotik sendromlar klinikte sıkça karşımıza çıkmaktadır. Nadir görülmeleri nedeniyle kesin tanıları genellikle dışlama yoluyla konulan bu sendromların tedavisinde, primer hastalık olan lenfomanın ortadan kaldırılması esastır. Onkologların öncülüğünde yürütülen multidisipliner bir yaklaşım, semptomatik tedavilerle birlikte hastaların yaşam kalitesini artırmada ve paraneoplastik bozuklukların hızlıca kontrol altına alınmasında hayati bir öneme sahiptir.
Lymphomas are malignancies originating from lymphocytes, the cornerstone of the immune system, and they can lead to a wide spectrum of clinical manifestations within the organism. Categorized into two primary groups as Hodgkin and Non-Hodgkin lymphoma, these diseases frequently trigger paraneoplastic syndromes (PNS), which are rare disorders not directly caused by local tumor invasion or metastasis. In lymphoma patients, the most common systemic symptoms associated with PNS are fever, weight loss, and night sweats; however, these syndromes are clinically classified into four main categories: hematological, neurological, dermatological, and renal disorders. Hematologically, autoimmune hemolytic anemia and immune thrombocytopenia are prevalent, whereas paraneoplastic cerebellar degeneration, limbic encephalopathy, and peripheral neuropathies represent the neurological spectrum. Dermatologically, paraneoplastic pemphigus and Sweet's syndrome are well-known, while renal involvements typically manifest as nephrotic syndromes like minimal change disease. Since these rare syndromes are often diagnosed by exclusion, the primary therapeutic strategy revolves around treating the underlying lymphoma itself. A multidisciplinary collaboration led by oncologists, combined with supportive and symptomatic therapies, is essential for effectively controlling paraneoplastic manifestations and significantly improving the patient's overall quality of life.
Referanslar
Hagler KT, Lynch JW Jr. Paraneoplastic manifestations of lymphoma. Clinical Lymphoma. 2004;5(1): 29-36. doi: 10.3816/clm.2004.n.007.
Sands J, Tuscano JM. Geoepidemiology and autoimmune manifestations of lymphoproliferative disorders. Autoimmunity Reviews. 2009;12(9): 335 – 341.
Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3): 209-249.
Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and Treatment. American Family Physician. 2020;101(1): 34-41.
Graus F, Ariño H, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2014;123(21):3230–3238.
Lechner K, Chen YA. Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma. Leukemia and Lymphoma. 2010;51(3): 469-74. doi: 10.3109/10428190903556394.
Sallah S, Sigounas G, Vos P, et al. Autoimmune hemolytic anemia in patients with non-Hodgkin’s lymphoma: characteristics and significance. Annals of Oncology. 2000;11: 1571-1577.
Xiros N, Binder T, Anger B, et al. Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin’s disease. Europen Journal of Haematology. 1988;40: 437-441.
Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New England Journal of Medicine. 2007;357: 2237-2247.
Norgaard M. Thrombosis in patients with primary chronic immune thrombocytopenia. Thrombosis research. 2012;130: 74-75.
Karakurt N, Uslu İ, Albayrak C, et al. Neonates born to mothers with immune thrombocytopenia: 11 years experience of a single academic center. Blood Coagul Fibrinolysis. 2018;29(6): 546-550.
Bradley SJ, Hudson GV, Linch DC. Idiopathic thrombocytopenic purpura in Hodgkin's disease: a report of eight cases. Clinical Oncology (The Royal College of Radiologists). 1993;5(6): 355-7. doi: 10.1016/s0936-6555(05)80085-8.
Cooper N, Ghanima W. Immune Thrombocytopenia. New England Journal of Medicine. 2019;381(10): 945-955. doi: 10.1056/NEJMcp1810479. PMID: 31483965.
Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10): 1547-54. doi: 10.3324/haematol.2014.114561.
Briani C, Vitaliani R, Grisold W, et al. PNS Euronetwork Spectrum of paraneoplastic disease associated with lymphoma. Neurology. 2011;76(8): 705-710.
Shams’ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain. 2003;126(6): 1409-1418.
Darnell RB, Posner JB. Paraneoplastic Syndromes. Contemporary Neurology Series 79. 2011Oxford, UKOxford University Press.
Bernal F, Shams’ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology. 2003;60(2): 230-234.
Pfliegler G, Posan E, Glaub D, et al. Hodgkin’s disease and memory loss: another case of Ophelia syndrome. British Journal of Haematology. 1990;74: 232.
Guletkin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain. 2000;123: 1481-494.
Mat A, Adler H, Merwick A, et al. Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology. 2013;80(14): 1349-1350.
Griggs JJ, Commichau CS, Rapoport AP, et al. Chronic inflammatory demyelinating polyneuropathy in non-Hodgkin’s lymphoma. American Journal of Hematology. 1997;54: 332-334.
Kasamon YL, Nguyen TN, Chan JA, et al. EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency. American Journal of Hematology. 2002; 69: 289-293.
Gordon PH, Rowland LP, Younger DS, et al. Lymphoproliferative disorders and motor neuron disease: an update. Neurology. 1997;48: 1671-78.
Schold SC, Cho ES, Somasundaram M, Posner JB. Subacute motor neuronopathy: a remote effect of lymphoma. Annals of Neurology. 1979;5(3): 271-287.
Wieczorek M, Czernik A. Paraneoplastic pemphigus: a short review. Clinical, Cosmetic and Investigational Dermatology. 2016;9: 291-295.
Gille J, Spieth K, Kaufmann R. Sweet’s syndrome as initial presentation of diffuse large B-cell lymphoma. Journal of The American Academy of Dermatology. 2002;46: 11-13.
Cohen PR, Kurzrock R. Sweet's syndrome: a review of current treatment options. American Journal of Clinical Dermatology. 2002;3(2): 117-131. doi:10.2165/00128071-200203020-00005.
Vassallo C, Ciocca O, Arcaini L, et al. Eosinophilic folliculitis occurring in a patient affected by Hodgkin lymphoma. International Journal of Dermatology. 2002;41: 298-300.
Ehst BD, Minzer-Conzetti K, Swerdlin A, et al. Cutaneous manifestations of internal malignancy. Current Problems in Surgery. 2010;47(5): 384-445. doi: 10.1067/j.cpsurg.2010.01.003.
Sfrijan D, Tieranu I, Necula I, et al. Nephrotic Syndrome, Paraneoplastic Syndrome Associated to Hodgkin Lymphoma. Maedica (Bucur). 2016;11(1): 64-67.
Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney International. 1999 Jul;56(1): 355-77. doi: 10.1046/j.1523-1755.1999.00548.x.
Okogbaa, John, and Lakeasha Batiste. “Dermatomyositis: An Acute Flare and Current Treatments.” Clinical Medicine Insights Case reports. 2019;12: 1179547619855370.
Yadlapati S, Efthimiou P. Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk? Biomed Research International. 2016;2016: 8631061. doi: 10.1155/2016/8631061.
Ikeda K, Ohno H, Hane M, et al. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. The Journal of Clinical Endocrinology and Metabolism. 1994;79(5): 1322-7. doi: 10.1210/jcem.79.5.7962324.
Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 1993;82(5): 1383-1394.
Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Therapatics and Clinical Risk Management. 2015;4(11): 1779-88. doi: 10.2147/TCRM.S83681.
